Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial
British Journal of Haematology · 2026-04 · 208 (4) · 1424-1428
DOI: 10.1111/bjh.70335 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 26.01.2026. Verfasst von Jia Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: National Natural Science Foundation Project of China, Tianjin Municipal Natural Science Foundation, Tianjin Science and Technology Planning Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, Tianjin, China.
- Department of Neurosurgery, Huanhu Hospital, Tianjin, China.
- Department of Hematology, Xingtai People's Hospital, Xingtai, China.
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
ORCID-Profile: Huijuan Jiang, Rong Fu
Förderung
- National Natural Science Foundation Project of China
- Tianjin Municipal Natural Science Foundation
- Tianjin Science and Technology Planning Project
- Tianjin Municipal Health Commission Project
- Natural Science Foundation of Tianjin Municipality
- Tianjin Municipal Science and Technology Program
Zitieren
APA
Song, J., Jiang, H., Ding, K., Liu, H., Wang, Y., Gao, S., Ren, Y., Liu, Z., Zhuo, J., Li, B., Wang, G., Jiao, Z., Gao, D., & Fu, R. (2026). Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial. British Journal of Haematology, 208(4), 1424-1428. https://doi.org/10.1111/bjh.70335
Vancouver
Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, et al. Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial. British Journal of Haematology. 2026;208(4):1424-1428. doi:10.1111/bjh.70335
BibTeX
@article{Song2026,
author = {Song, Jia and Jiang, Huijuan and Ding, Kai and Liu, Hui and Wang, Yihao and Gao, Shan and Ren, Yue and Liu, Zhaoyun and Zhuo, Jie and Li, Bing and Wang, Guokai and Jiao, Zongjiu and Gao, Da and Fu, Rong},
title = {Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {4},
pages = {1424--1428},
doi = {10.1111/bjh.70335}
}
EUVIMED